production was assayed in HCAs and human coronary artery endothelial cells (HCAECs) using dihydroethidium and dichlorodihydrofluorescein histofluorescence, respectively. Superoxide was quantified by HPLC separation of dihydroethidium products. Diameter changes of HCAs were measured by videomicroscopy. NADPH oxidase subunits Nox1, Nox2, Nox4, p22, p47, and p67 were each expressed in HCA endothelium. In HCAs or HCAECs incubated with dihydroethidium and dichlorodihydrofluorescein, BK induced superoxide and H 2 O 2 formation, which was inhibited by gp91ds-tat or apocynin but not by gp91scram-tat or rotenone. HPLC analysis confirmed that BK specifically induced superoxide production. Gp91ds-tat reduced vasodilation to BK but not to papaverine. 14,15-EEZE (an EET antagonist) further reduced the residual dilation to BK in the presence of gp91ds-tat, but had no effect in the presence of gp91scram-tat, suggesting that NADPH oxidase-derived ROS modulate EET bioavailability. 
H
2 O 2 is a reactive oxygen species (ROS) that functions as an endothelium-derived hyperpolarizing factor (EDHF) in some circulatory beds, including HCAs. [1] [2] [3] [4] EDHF is particularly important in the microcirculation, where vascular resistance is regulated. As an EDHF, H 2 O 2 may compensate to maintain adequate perfusion in states of heightened oxidative stress such as cardiovascular disease, where nitric oxide (NO)-mediated vasodilation is impaired. In addition to its direct vasodilator properties, H 2 O 2 can modulate bioavailability of EETs, cytochrome P450 (CYP)-derived metabolites of arachidonic acid that also function as EDHFs. 5 H 2 O 2 arises by enzymatic or spontaneous dismutation of the superoxide anion. Superoxide is generated from numerous intracellular sources, including mitochondria, 4 CYPs, 6 and NADPH oxidases. 7 The canonical Nox2-containing NADPH oxidase was originally identified in phagocytes, where it mediates the microbicidal respiratory burst; however, Nox2 as well as alternative NADPH oxidases containing Nox1 or Nox4 are now recognized as an important source of ROS in vascular tissue as well. 8 Although the pathological role of NADPH oxidase is well defined by its heightened participation in a variety of vascular diseases, 7, 9 its possible contribution to physiological vascular stimuli is less clear, especially in the human heart. This study was conducted to examine the putative role of NADPH oxidase in mediating dilation to BK in HCAs. Published data indicate that both flow-induced 3 and BK-induced 5 dilation of HCAs are sensitive to catalase, implicating a role for H 2 O 2 in these responses. Evidence points to the mitochondrial electron transport chain as a critical source of ROS in response to shear stress, 4 but the enzymatic source of H 2 O 2 in response to BK is not known. The present study provides the first evidence that NADPH oxidase produces ROS in the human coronary microcirculation and that this enzyme is critical to the mechanism of dilation to BK, a physiological vasomotor agonist. Specifically, we examined whether NADPH oxidase is (1) expressed in HCAs, (2) responsible for BK-induced ROS production, (3) required for BK-induced dilation, and (4) responsible for oxidative inhibition of the EET-mediated component of BK-induced dilation.
Methods
For complete details of immunohistochemistry, fluorescence microscopy, HPLC, and videomicroscopy protocols, as well as a listing of materials, please refer to the online supplement at http://atvb. ahajournals.org.
Tissue Acquisition
Fresh right atrial appendages were obtained as discarded surgical specimens from patients undergoing cardiopulmonary bypass procedures, as reported previously. 3, 10 All tissue acquisition procedures and experimental protocols were approved by the appropriate Institutional Review Boards. Demographic data and diagnoses were obtained at the time of surgery.
Immunohistochemistry
Immunohistochemistry was performed to visualize NADPH oxidase subunit expression as reported previously. 
HPLC Measurement of Superoxide
HPLC separation and quantification of oxidized DHE products were performed as described previously. 14 Briefly, HCAs were incubated with the NADPH oxidase inhibitor apocynin (3ϫ10 Ϫ3 mol/L) or vehicle. DHE was then added and HCAs were incubated with BK (10 Ϫ6 mol/L) or vehicle. DHE metabolites were then extracted, separated by HPLC, and quantified. 14 
Measurement of HCA Dilation by Videomicroscopy
Dilation of HCAs was observed by videomicroscopy as described previously. 10 Briefly, isolated HCAs were cannulated, pressurized, equilibrated, and constricted with KCl (50 mmol/L) to assess viability. Only vessels that constricted Ͼ30% were used for subsequent experiments. 3, 10, 15 After washing, vessels were constricted 30% to 50% with endothelin-1 (ET-1, 5ϫ10
Ϫ10 to 10 Ϫ9 mol/L). Although published data indicate little contribution of NO or prostacyclin to BK-induced dilation of HCAs, 15 all experiments were performed in the presence of N-nitro-L-arginine methyl ester (10 Ϫ4 mol/L, an NO synthase inhibitor) and indomethacin (10 Ϫ5 mol/L, a cyclooxygenase inhibitor) to eliminate any residual confounding effects of these vasodilators. Cumulative concentrations of BK (10 Ϫ10 to 10 Ϫ6 mol/L) were then added and steady state diameters were measured. After washing, gp91ds-tat (5ϫ10 Ϫ5 mol/L) or gp91scram-tat peptide (5ϫ10 Ϫ5 mol/L) was introduced both in the superfusate and intraluminally under a brief period of flow. In other vessels, 14,15-epoxyeicosa-5(Z)-enoic acid (EEZE, 10 Ϫ5 mol/L, an EET antagonist 16 ) was coadministered with gp91ds-tat or gp91scram-tat. After equilibration, HCAs were again constricted with ET-1, and cumulative concentrations of BK were again applied. At the end of each experiment, papaverine (10 Ϫ4 mol/L, an endothelium-independent vasodilator) was added to determine the maximum diameter.
Statistical Analyses
HPLC data, maximum percent vasodilation (%MD), EC 50 , and fluorescence intensities were evaluated using paired or unpaired Student t tests, whenever applicable. To compare concentrationresponse relationships, a 2-factor repeated measures ANOVA was used. When a significant difference was observed between curves (PϽ0.05), responses at individual concentrations were compared using a Holm-Sidak multiple comparison test. Multiple stepwise regression analyses were used to detect the influence of underlying diseases, age, and gender on vasodilation at various concentrations. All analyses were performed using SigmaStat, version 3.1. Statistical significance was defined as PϽ0.05. All data are described as meanϮSEM; nϭnumber of patients or experiments.
Results
Atrial appendages were obtained from 55 patients, yielding 135 HCAs with a mean internal diameter of 164Ϯ7 m. Patient demographic information is summarized in the Table.
Expression of NADPH Oxidase Subunits
To investigate whether NADPH oxidase may be a source of ROS in HCAs, immunohistochemistry was used to evaluate expression of NADPH oxidase subunits. As shown in Figure  1 , the catalytic subunits Nox1, Nox2, and Nox4 as well as the regulatory subunits p22, p47, and p67 are each expressed in the endothelium. Nonspecific staining was not observed in the absence of primary antibodies or in the presence of preimmune isotype control antibodies. Consistent with these findings, Western blot analysis of HCAEC protein demonstrated expression of Nox2, Nox4, and p22 (supplemental Figure II) . These findings provide indirect evidence that NADPH oxidase may be a source of ROS in HCAs.
Bradykinin-Induced Reactive Oxygen Species Production in HCAECs
It was recently reported that the endothelium is required for BK-induced ROS production in intact HCAs 5 ; however, it is not known whether ROS actually originate from endothelial cells in this context, nor has the enzymatic source of ROS been determined. To assess whether endothelial NADPH oxidase is required for ROS production in response to BK, superoxide and H 2 O 2 formation was assayed by DHE and DCFH histofluorescence, respectively. In HCAECs, superox- 
Bradykinin-Induced Reactive Oxygen Species Production in HCAs
To further assess whether NADPH oxidase is required for BK-induced ROS production, DHE and DCFH histofluorescence was performed on intact HCAs. As shown in Figure 3 
Quantification of Bradykinin-Induced Superoxide Production
Although DHE histofluorescence suggests that BK induces superoxide formation, this method has an important limita- tion. When oxidized, DHE forms 2 fluorescent products (2-hydroxyethidium, 2-OH-E ϩ , and ethidium, E ϩ ) with overlapping emission spectra; however, only 2-OH-E ϩ is specific for superoxide. 17 To specifically assess and quantify superoxide, we separated oxidized products of DHE from isolated HCAs using HPLC. As seen in Figure 4, 
Contribution of NADPH Oxidase to Bradykinin-Induced Dilation
To determine whether NADPH oxidase is a functionally relevant source of H 2 O 2 , HCA vasodilation was measured using videomicroscopy. As shown in Figure 5 , BK elicited a concentration-dependent dilation (% maximum dilation [MD] 93Ϯ3 and ϪlogEC 50 7.8Ϯ0.3, nϭ10) that was inhibited by gp91ds-tat (%MD 49Ϯ5 and ϪlogEC 50 6.7Ϯ0.1, nϭ5, PϽ0.05 versus BK alone) but not by gp91scram-tat (%MD 82Ϯ3 and ϪlogEC 50 7.7Ϯ0.3, nϭ5, Pϭns versus BK alone). Interestingly, BK-induced dilation was not influenced by sex, age, surgical procedure, or underlying disease. Dilation to papaverine was not altered in the presence of either gp91ds-tat or gp91scram-tat, indicating that these peptides do not directly impair vascular smooth muscle cell (VSMC) vasodilator capacity. Taken together, these results suggest that NADPH oxidase is required for BK-induced dilation.
NADPH Oxidase-Derived H 2 O 2 Reduces the EET-Mediated Component of BK-Induced Dilation
Previous studies indicate that BK-induced dilation is predominantly mediated by H 2 O 2 ; however, a prominent residual dilation occurs in the presence of catalase that is mediated by EETs. 5 This secondary mechanism is masked by an inhibitory effect of H 2 O 2 on CYP enzymatic activity, which reduces EET production; however, the source of ROS in this context is unknown. To determine whether NADPH oxidase-derived H 2 O 2 reduces the EET-mediated component of BK-induced dilation, EEZE was coadministered with gp91ds-tat or gp91scram-tat. Interestingly, the residual dilation to BK in the presence of gp91ds-tat was markedly inhibited by EEZE (%MD 9Ϯ3 versus 45Ϯ6 and ϪlogEC 50 6.5Ϯ0.1 versus 6.7Ϯ0.1 with gp91ds-tat alone, nϭ5, PϽ0.05, Figure 5 ). However, there was no effect of EEZE in the presence of gp91scram-tat. These results suggest that EETs mediate dilation to BK when NADPH oxidase is inhibited, and that NADPH oxidase-derived H 2 O 2 modulates the bioavailability or action of EETs.
Discussion
This study is the first to directly investigate a role for NADPH oxidase in the human coronary microcirculation. The novel findings of the present study are 4-fold. First, NADPH oxidase is expressed in HCAs. Second, BK induces endothelial ROS production in an NADPH oxidase-dependent manner. Third, NADPH oxidase is required for BK-induced dilation. Fourth, an EET-mediated component of BK-induced dilation is unmasked when NADPH oxidase is inhibited. Taken together, these data suggest that NADPH oxidase is a functionally relevant source of ROS that may modulate vasomotor tone not only by producing H 2 O 2 , but also by modulating EET bioavailability.
NADPH Oxidase and Agonist-Induced ROS Production
Vascular NADPH oxidase activity is induced by several physiological stimuli. The contribution of NADPH oxidase to angiotensin II (AngII)-induced ROS production in VSMCs is well established, where it plays a role in AngII-dependent hypertension and VSMC hypertrophy. 18 -20 NADPH oxidase is also activated by mechanical stimulation, 21 and its activation may play a role in atherogenesis in areas of oscillatory shear stress. 22 Despite evidence that BK induces H 2 O 2 production in the coronary circulation, 2, 5 little is known about the source of ROS in response to this agonist. BK induces H 2 O 2 release from porcine coronary microvessels in a manner that requires the endothelium; however, the enzymatic source of H 2 O 2 in this model has not yet been characterized. 2 The present study suggests that NADPH oxidase in endothelial cells may be a source of ROS in response to BK. Inhibition of NADPH oxidase reduces BK-induced dilation, indicating that this enzyme complex is a functionally relevant mediator of vasodilation. Although gp91ds-tat does not completely abolish this response, the magnitude of inhibition is similar to the published inhibitory effect of catalase on BK-induced dilation in these vessels. 5 It is a somewhat unexpected finding that NADPH oxidase mediates a vasodilator response to BK in light of substantial evidence implicating this enzyme as an effector of AngII signaling and impaired NO-dependent vasodilation. 19, 20 Animal studies indicate that AngII-induced NADPH oxidase activity acutely impairs endothelium-dependent vasodilation 23 and chronically promotes VSMC hypertrophy 18 and hypertension. 12, 23 It is not known how AngII and BK elicit opposing vascular effects through activation of the same enzyme; however, the present study suggests that critical agonist-dependent or cell-dependent differences in NADPH oxidase activation occur. Whereas NADPH oxidase in VSMCs serves as an effector of AngII to promote vasoconstriction and hypertrophy, NADPH oxidase in endothelial cells may serve as an effector of BK to modulate acute vasodilatory function. It is also possible that NADPH oxidase may have differential roles in normal versus diseased vessels. In nondiseased vessels where NO-mediated dilation is significant, 10 activation of NADPH oxidase may have a net constricting effect by reducing NO bioavailability. In contrast, diseased HCAs mediate dilation via EDHFs and not via NO 10 ; therefore, activation of NADPH oxidase to generate H 2 O 2 may have a net dilating effect. If so, the ratio of NADPH oxidase activation in endothelial cells versus gp91ds-tat or gp91scram-tat (nϭ6, 3, and 3,  respectively) . C, BK-induced dilation is not reduced by EEZE in the presence of gp91scram-tat (nϭ5). D, The residual dilation to BK in the presence of gp91ds-tat is inhibited by EEZE (nϭ5).
†PϽ0.05 vs vehicle curve, *PϽ0.05 vs vehicle at specific dose. n indicates number of patients.
VSMCs may be an important factor in the regulation of cardiovascular parameters such as blood pressure and tissue perfusion.
It is widely recognized that the ratio of BK to AngII plays an important role in blood pressure regulation. BK receptor B 2 knockout mice exhibit elevated basal blood pressure as well as an exaggerated blood pressure response to AngII, 24 suggesting that BK dampens the vasoconstrictive effects of AngII. Angiotensin I converting enzyme (ACE) inhibitors exploit this relationship between BK and AngII. ACE catalyzes not only AngII formation from its inactive precursor, angiotensin I, but also inactivates BK. Importantly, the beneficial cardiovascular effects of ACE inhibitors have been attributed not only to reduced AngII bioavailability, but also in part to enhanced BK bioavailability. 25 The present study suggests an intriguing mechanism that may underlie the antihypertensive effect of ACE inhibitors; namely, that they decrease blood pressure not only by suppressing AngIIinduced NADPH oxidase activity in VSMCs, but also by promoting NAPDH oxidase activation in endothelial cells through enhanced BK bioavailability. Although ACE inhibitors inhibit NADPH oxidase activity in human mononuclear leukocytes 26 and an AngII receptor blocker reduces AngIIinduced activation of NADPH oxidase in rats, 23 additional studies will be necessary to define the effect of ACE inhibitors on endothelial and smooth muscle NAPDH oxidase in humans.
Potential Study Limitations
An important limitation of the present study is the lack of quantification of H 2 An additional limitation of this study is a lack of direct EET measurements. Although numerous attempts were made to quantify EETs released from HCAs using HPLC or liquid chromatography electrospray-ionization mass spectrometry, the sensitivity of currently available methods is insufficient to consistently and reproducibly measure EETs from such small samples. We were also unable to demonstrate EET production from HCAECs, a finding consistent with the observation that endothelial cells rapidly lose CYP expression and activity in culture. 27 An alternative explanation is that HCAs may not, in fact, produce EETs. Although this possibility cannot be ruled out, we believe it is less likely, as CYPs and the EET-metabolizing soluble epoxide hydrolase enzyme are robustly expressed in HCA endothelium, 11 suggesting that HCAs are capable of producing and metabolizing EETs. Indeed, vasodilation in the presence of gp91ds-tat is blocked by EEZE, indirectly suggesting that EETs are produced when NADPH oxidase is inhibited. This finding is consistent with published data indicating that EET production is sensitive to H 2 O 2 . 11 The present study indicates that Nox1, Nox2, and Nox4 are each expressed in HCAs; however, their relative physiological importance in this model is unknown. BK-induced dilation is reduced by gp91ds-tat, suggesting that Nox2 mediates this response; however, other Nox isoforms may also contribute to this response, as gp91ds-tat cross-reactivity is theoretically possible. 12 Nox4 in particular may contribute to H 2 O 2 -mediated vasodilation, as Nox4 produces much more H 2 O 2 than superoxide. 28 Highly specific inhibitors will therefore be necessary to determine whether Nox1 or Nox4 are also functional in HCAs.
An additional limitation of this study is the lack of heart tissue from healthy subjects, as this is rarely obtainable. However, this limitation is offset by the unique advantage of studying NADPH oxidase in the clinically-relevant context of chronic cardiovascular disease and its risk factors, conditions that cannot be adequately mimicked in animal models. Recent evidence indicates that NADPH oxidase activity may be elevated in cardiovascular disease, 7 rendering an evaluation of NADPH oxidase critical in the diseased human heart.
Clinical Implications
With the expanding body of evidence implicating NADPH oxidase in the pathogenesis of atherosclerosis, hypertension, and inflammation, pharmacological inhibition of this enzyme has emerged as a potential therapeutic approach for these diseases. 7 This study suggests a potential limitation of this approach, as NADPH oxidase inhibitors may acutely reduce agonist-induced vasodilation. On the other hand, the acutely detrimental effects of NADPH oxidase inhibition, if any, may be partially offset by enhanced EET bioavailability. H 2 O 2 is a proinflammatory and proatherosclerotic molecule, 29 but EETs have antiinflammatory and vasculoprotective effects, 30 similar to NO. Although NADPH oxidase inhibition affects human coronary microvascular function in vitro, additional studies will be necessary to understand the global effects of NADPH oxidase inhibitors in vivo.
Conclusions
The present study supports a role for NADPH oxidase as a modulator of vasomotor tone in the human coronary microcirculation. NADPH oxidase is a functionally relevant source of ROS that not only mediates agonist-induced vasodilation, but may also reduce EET bioavailability. NADPH oxidase activity may therefore influence coronary vascular resistance and myocardial perfusion, but its physiological importance in vivo remains to be determined.
